Skip to main content
. Author manuscript; available in PMC: 2023 Apr 10.
Published in final edited form as: J Oncol Pharm Pract. 2021 Jun 17;28(6):1340–1349. doi: 10.1177/10781552211024727

Table 2.

Baseline characteristics by treatment center.

Total (n = 44) Johns Hopkins Hospital (n = 24) University of Maryland Medical Center (n = 20) P-value*
Sex, % female 50 37.5 65 0.129
Age, years, mean (range; SD) 50.6 (20–87; 16.7) 50.9 (20–83; 15.2) 50.3 (23–87; 18.8) 0.905
Weight, kg, median (range) 87.7 (52.2–228.5) 85.2 (52.2–149.5) 88.3 (61.7–228.5) 0.962
BMI, kg/m2, median (range) 30.2 (18.1–62) 27.5 (18.1–55.7) 31.4 (22.5–62.0) 0.311
WHO Obesity Class Underweight: 1 Underweight: 1 Underweight: 0
Normal: 7 Normal: 4 Normal: 3
Overweight: 13 Overweight: 10 Overweight: 3
Obese: 12 Obese: 2 Obese: 10
Obese II: 3 Obese II: 1 Obese II: 2
Obese III: 8 Obese III: 6 Obese III: 2
Starting ATO dose, mg, median (range) 12 (7.8–20) 10.5 (7.8–17.0) 13.0 (9.3–20.0) 0.006
Starting ATO dose > 10 mg, n (%) 29 (65.9) 12 (50.0) 17 (85.0) 0.025
Dose, mg/kg, median (range) 0.15 (0.067–0.157) 0.144 (0.067–0.157) 0.149 (0.088–0.157) 0.015
Baseline AST, IU/L, median (range) 25 (11–155) 21.5 (11–39) 32.5 (15–155) 0.003
Baseline ALT, IU/L, median (range) 26.5 (8–173) 22.5 (8–47) 35.5 (17–173) 0.001
Baseline TBILI, mg/dL, median (range) 0.6 (0.2–3.2) 0.6 (0.2–3.2) 0.7 (0.2–1.5) 0.222
Baseline QTc, msec, median (range) 415 (296–479) 415 (381–453) 416 (296–479) 0.888
Duration of induction, days, median (range) 28 (3–67) 28 (14–67) 28 (3–34) 0.953
Cumulative ATO dose during induction mg, mean (range; SD) 333.5 (140–540; 91.0) 301.1 (140–514.4; 80.6) 375.0 (240–540; 88.6) 0.008
Dose omissions for any reason, n 6 4 2
Dose reductions for any reason, n 3 2 1
CR after induction, n (%) 41 (93.2) 23 (95.8) 18 (90) 0.583
Relapse, n 0 0 0
Death, n 3 1 2

WHO: World Health Organization.

*

P-values generated with Mann Whitney U test (non-parametric) and t-test (normally distributed).